Century Therapeutics, Inc. (IPSC): Price and Financial Metrics
IPSC Price/Volume Stats
Current price | $0.73 | 52-week high | $5.51 |
Prev. close | $0.76 | 52-week low | $0.72 |
Day low | $0.72 | Volume | 347,479 |
Day high | $0.78 | Avg. volume | 518,972 |
50-day MA | $1.09 | Dividend yield | N/A |
200-day MA | $1.89 | Market Cap | 62.07M |
IPSC Stock Price Chart Interactive Chart >
Century Therapeutics, Inc. (IPSC) Company Bio
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPSC Price Returns
1-mo | -31.78% |
3-mo | -49.31% |
6-mo | -57.56% |
1-year | -83.60% |
3-year | -94.15% |
5-year | N/A |
YTD | -27.72% |
2024 | -69.58% |
2023 | -35.28% |
2022 | -67.65% |
2021 | N/A |
2020 | N/A |
Loading social stream, please wait...